Published on 29/11/2025

Mock Recalls/Simulations Focused on Chain-of-Identity and Chain-of-Custody

Understanding Chain-of-Identity and Chain-of-Custody

The concepts of COI and COC are foundational in the production and distribution of biologics and ATMPs. COI refers to the process of verifying the origin and integrity of biological materials throughout their lifecycle, while COC ensures that the materials are being handled and maintained under controlled conditions.

Regulatory Frameworks and Guidelines

Regulatory bodies such as the FDA, EMA, and the WHO monitor compliance with guidelines that govern COI and COC. Familiarity with the ICH Q5A(R2) guidelines, which focus on viral safety evaluations of biological products, is essential in ensuring adherence to these regulations. These guidelines also emphasize the importance of maintaining traceability of the materials and proper documentation practices.

The Role of CQAs in Viral Clearance

Critical quality attributes (CQAs) such as potency and identity must be rigorously evaluated and controlled throughout the manufacturing process. A comprehensive understanding of how these attributes align with COI and COC is crucial for regulatory compliance and product viability.

Preparing for Mock Recalls: Step-by-Step Guide

Conducting mock recalls is an essential practice in validating the COI and COC processes. Follow these steps to design an effective mock recall process:

Step 1: Define the Scope and Purpose

• Determine the specific objectives of the mock recall, ensuring alignment with regulatory expectations.
• Identify whether the recall will focus on specific products, batches, or a broader range of operations.

Step 2: Form a Cross-Functional Team

A successful mock recall requires collaboration across various departments. Assemble a team that includes representatives from:

• Quality Assurance (QA)
• Quality Control (QC)
• Regulatory Affairs
• Production and Supply Chain

Step 3: Develop a Mock Recall Plan

Craft a detailed plan outlining the procedures and responsibilities during the mock recall, including:

• Identification of materials involved in the mock recall.
• Communication strategies for informing stakeholders.
• Documentation requirements and methods of tracking the recall process.

Step 4: Execute the Mock Recall

Implement the plan with precision and attention to detail. During execution:

• Test the triggers for initiating a recall.
• Track the movement and processing of the materials in question.
• Evaluate the response time of each department and the effectiveness of communication.

Step 5: Analyze Results and Identify Gaps

Post-mock recall, conduct a thorough evaluation of the process:

• Identify areas of strength and weakness.
• Gather feedback from all team members involved.
• Document findings and update procedures as necessary.

Implementing Viral Clearance Validation Procedures

With increasingly complex products, establishing robust viral clearance validation processes is critical. Here’s a structured approach:

Understanding the Importance of Viral Clearance

Viral clearance is essential to mitigate the risk of contamination, which is particularly pertinent for biologics and ATMPs. Implementing effective clearance strategies helps maintain product integrity and ensures patient safety.

Step 1: Risk Assessment

Begin by evaluating potential viral risks associated with the manufacturing process. This assessment involves:

• Identifying hazards related to biological materials used in production.
• Analyzing previous data from spiking studies to understand viral loads.

Step 2: Designing Spiking Studies

Spiking studies determine the robustness of viral clearance methods:

• Design experiments that mimic actual conditions, ensuring the realism of the validation.
• Use appropriate virus strains relevant to the product type to get realistic results.

Step 3: Validation of Clearance Methods

The next step is to validate the viral clearance methods:

• Conduct experiments following the designed protocols and gather data meticulously.
• Analyze the results against predetermined acceptance criteria.

Utilizing Closed and Single-Use Systems in Validation

Closed and single-use systems have become integral to modern pharmaceutical manufacturing, particularly for biologics and ATMPs. Understanding their role is essential in the context of viral clearance validation and COI/COC compliance.

Benefits of Closed Systems

• Reduced contamination risk through minimized open handling.
• Streamlined workflows that enhance efficiency and control.
• Improved tracking of materials, facilitating COI and COC compliance.

Implementation Considerations for Single-Use Systems

Single-use systems present unique challenges and opportunities:

• They facilitate ease of use and reduce cleaning validation burdens.
• Validate their sterility and integrity to ensure compliance with aseptic controls Annex 1.

Tailoring PPQ and CPV Practices for ATMPs

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are crucial elements of the validation lifecycle:

Customizing Strategies for ATMP Validation

As biologics and ATMPs often present unique characteristics and challenges, tailoring PPQ and CPV is essential:

• Utilize real-time data to inform decisions throughout the lifecycle.
• Integrate feedback mechanisms for continuous improvement based on findings from mock recalls.

Emphasizing Training and Awareness

All staff involved in the production, validation, and QA/QC processes should receive adequate training concerning COI/COC compliance, as well as the importance of viral clearance validation.

Conclusion

In summary, conducting thorough mock recalls and systematically validating processes for viral clearance, as well as implementing robust COI and COC measures, is critical in today’s biopharmaceutical manufacturing environment. By following these structured steps, organizations can enhance their compliance with regulatory expectations, streamline operations, and maintain the highest quality standards for their products. Emphasis on continual training and assessment will ensure that pharmaceutical professionals are well-equipped to meet the challenges of this evolving landscape.

Staying informed on updates from regulatory bodies and advancing technology will be key in maintaining compliance and ensuring the safety and efficacy of biologic and ATMP products.